Evidence map›Paper›PMID 41469820›Full record

ArticleScientific reports2025

Nanostructured lipid carrier of oregano essential oil for controlling Tuta absoluta with minimal impact on beneficial organisms.

Asmar Soleymanzadeh, Orouj Valizadegan, Hamed Hamishehkar

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Asmar SoleymanzadehDepartment of Plant Protection, Faculty of Agriculture, Urmia University, Urmia, Iran.
Orouj ValizadeganDepartment of Plant Protection, Faculty of Agriculture, Urmia University, Urmia, Iran. O.valizadegan@urmia.ac.ir.
Hamed HamishehkarDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuta absoluta is a significant invasive pest, severely impacting the global tomato industry. Prolonged application of chemical insecticides has led to varying degrees of resistance in T. absoluta populations. Additionally, chemical insecticides are causing serious threats to the environment. Aiming to develop a novel bioinsecticide based on Origanum vulgare essential oil (OVE) against T. absoluta, we carried out its nanostructured lipid carrier formulation (OVE-NLC). The obtained OVE-NLC had spherical particles approximately 94.26 nm in size with a uniform size distribution of less than 0.3 and a zeta potential of - 18.75 mV. The formulated NLC also had encapsulation efficiency up to 96% and was stable at 25 °C for 3 months. The FTIR results indicated no significant chemical interaction between EO and NLC components. OVE-NLC demonstrated significant toxicity towards T. absoluta larvae and a remarkable oviposition deterrence for females. The nanoformulation also negatively affected the population growth parameters of T. absoluta, significantly reducing its fecundity by approximately 70% and 42% in contact and topical assays, respectively. Additionally, OVE-NLC had no lethal effects on the generalist predator Macrolophus pygmaeus and pollinator bee Bombus terrestris as non-target organisms. Results suggested that OVE-NLC could be successfully used as a potential tool for tomato integrated pest management programs.

Indexed as

InsecticidesLipidsMothsNanostructuresOils, VolatileOriganumAnimalsDrug CarriersFemaleLarvaPlant OilsSolanum lycopersicumDrug CarriersInsecticidesLipidsOils, VolatilePlant OilsBioinsecticideNanotechnologyPollinatorPredatorSide effectTuta absoluta

Identifiers

PMID41469820
PMCPMC12848087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.